Welcome to Cellectis.com - Home

cellectis.com

Description: Cellectis. Cellectis is a clinical-stage biopharmaceutical company developing the Next-Generation CAR T-Cells to Cure Cancer.

Google PR 5

Trustworthiness Good
Avg. Daily Visitors 252

Child Safety Unknown
Avg. Daily Pageviews 505

Privacy Good

Home | Cellectis

Cellectis.com: get to the top rated Cellectis pages and content popular with Germany-based Cellectis.com users or check the following digest to find out more. Cellectis.com is a malware-free website without age restrictions, so you can safely browse it. It seems that Cellectis team are just starting to conquer the social media and they have already achieved a promising result — 44 user activities so far (LinkedIn dominates with around 99% of all user reactions). Cellectis.com is hosted with CELESTE SAS in France. Cellectis traffic is estimated at around 7.57K visits per month.

Visit cellectis.com

Domain info

Location:	France
Registrant:	REDACTED FOR PRIVACY (CHOULIKA, ANDRE)
Hosted by:	CELESTE SAS
Registrar:	Gandi SAS
Subnetworks:	178.16.164.60

Alexa's Traffic Estimates & Trends

Traffic Rank:	434 484
Month Average Daily Reach:	0.000009	-70.8%
Month Average Daily Pageviews:	0.000001	-80.3%

More details from Alexa

Social Media Activities

Facebook likes: -
Twitter mentions: -
Google pluses: 1
LinkedIn mentions: 43
Pinterest pins: -
StumbleUpon views: -

Web Safety

This website is malware-free.
Status ok

See Google Transparency Report

Whois

Expand

Cellectis.com popular pages to visit

Chimeric Antigen Receptors | cellectis CARs are engineered molecules that, when present at the surface of T-cells, enable them to recognize specific proteins or antigens that are present on the surface of other cells. These receptors are...

Home | Cellectis Cellectis is a clinical-stage biopharmaceutical company developing the Next-Generation CAR T-Cells to Cure Cancer

Home | Cellectis Cellectis leverages its leadership in gene editing through its flagship technology, TALEN ®, which allows the company to create CAR T therapies to bring new hope to cancer patients through broadly av...